| Model Name | Description |
| KHOS/NP | Osteosarcoma model with p53 mutation and high metastatic potential; used to study chemoresistance and osteogenic differentiation pathways. |
| 143B | Highly aggressive osteosarcoma derived from the HOS line with KRAS transformation; TP53 mutant; widely used for metastasis and mitochondrial-targeted therapy studies. |
| SAOS-2 | Osteosarcoma model with homozygous TP53 deletion and RB1 mutation; non-metastatic, used in bone formation and mineralization research. |
| A204 | Rhabdomyosarcoma of epithelial origin; TP53 wild-type; sensitive to microtubule-targeting agents and used for pediatric soft tissue sarcoma studies. |
| Aska-SS | Synovial sarcoma model with SS18-SSX1 fusion; biphasic histology; used for studies on translocation-driven sarcomagenesis and epigenetic therapies. |
| HS-SY-II | Derived from human synovial sarcoma with SS18-SSX1 fusion; epithelial morphology; utilized in testing HDAC and EZH2 inhibitors. |
| Yamato-SS | Synovial sarcoma with SS18-SSX2 fusion transcript; monophasic spindle-cell subtype; used in fusion-driven oncogenesis and targeted therapy evaluation. |
| SJCRH30 | Alveolar rhabdomyosarcoma with PAX3-FOXO1 fusion; aggressive and metastatic; key model for testing targeted therapies in fusion-positive rhabdomyosarcoma. |
| SK-ES-1 | Ewing sarcoma model harboring EWSR1-FLI1 fusion; CD99-positive, highly proliferative; standard model for evaluating Ewing-specific targeted agents. |